摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(3,4-Dichlorophenyl)sulfanyl-6,7-difluoro-3-methyl-4-oxidoquinoxalin-1-ium 1-oxide | 691357-05-8

中文名称
——
中文别名
——
英文名称
2-(3,4-Dichlorophenyl)sulfanyl-6,7-difluoro-3-methyl-4-oxidoquinoxalin-1-ium 1-oxide
英文别名
——
2-(3,4-Dichlorophenyl)sulfanyl-6,7-difluoro-3-methyl-4-oxidoquinoxalin-1-ium 1-oxide化学式
CAS
691357-05-8
化学式
C15H8Cl2F2N2O2S
mdl
——
分子量
389.21
InChiKey
BLNVYZMQOGRXRV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.1
  • 重原子数:
    24
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.07
  • 拓扑面积:
    71.7
  • 氢给体数:
    0
  • 氢受体数:
    6

反应信息

  • 作为反应物:
    描述:
    2-(3,4-Dichlorophenyl)sulfanyl-6,7-difluoro-3-methyl-4-oxidoquinoxalin-1-ium 1-oxide间氯过氧苯甲酸 作用下, 以 氯仿 为溶剂, 反应 15.0h, 以80%的产率得到2-(3,4-Dichlorophenyl)sulfonyl-6,7-difluoro-3-methyl-4-oxidoquinoxalin-1-ium 1-oxide
    参考文献:
    名称:
    Synthesis, anti-mycobacterial, anti-trichomonas and anti-candida in vitro activities of 2-substituted-6,7-difluoro-3-methylquinoxaline 1,4-dioxides
    摘要:
    A new series of 23 6,7-difluoro-3-methyl-2-phenylthio/phenylsulfonyl/phenylsulfinyl/benzylamino/phenylamino-quinoxaline 1,4-dioxides variously substituted in the phenyl moiety, was synthesized and submitted to in vitro evaluation for anti-mycobacterial, anti-trichomonas, anti-candida, anti-mycoplasma and antibacterial activities. In anti-mycobacterial assays, several compounds resulted active (MIC90 = 2.0-4.0 mug/ml) against Mycobacterium tuberculosis H37Rv. Anti-trichomonas screening showed a generally good activity of all compounds (MBC = 0.39-25.0 mug/ml) versus Trichomonas vaginalis, in particular the derivatives 5a,d, 7a, 9 and 11c ranged 0.39-0.78 mug/ml (metronidazole MBC = 12.5 mug/ml). Results of anti-candida assays showed that derivatives 7a, 8a,d and 9 were active against several species of Candida (C. albicans, C. krusei, C. parapsilosis and C. glabrata), having MIC50 between 3.9 and 31.25 mug/ml. The latter compounds were also submitted to anti-mycoplasma assay against Mycoplasma hominis. the results obtained showed that 7a, 8a,d and 9 inhibited the growth of the mycoplasma at the concentration of 0.1 mg/ml. In antibacterial tests only a few compounds showed an MIC50 lower than 62.5 mug/ml against representative strains of Gram-positive and Gram-negative bacteria (Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, Vibrio alginolyticus and Pseudomonas aeruginosa). (C) 2003 Elsevier SAS. All rights reserved.
    DOI:
    10.1016/j.ejmech.2003.11.008
  • 作为产物:
    参考文献:
    名称:
    Synthesis, anti-mycobacterial, anti-trichomonas and anti-candida in vitro activities of 2-substituted-6,7-difluoro-3-methylquinoxaline 1,4-dioxides
    摘要:
    A new series of 23 6,7-difluoro-3-methyl-2-phenylthio/phenylsulfonyl/phenylsulfinyl/benzylamino/phenylamino-quinoxaline 1,4-dioxides variously substituted in the phenyl moiety, was synthesized and submitted to in vitro evaluation for anti-mycobacterial, anti-trichomonas, anti-candida, anti-mycoplasma and antibacterial activities. In anti-mycobacterial assays, several compounds resulted active (MIC90 = 2.0-4.0 mug/ml) against Mycobacterium tuberculosis H37Rv. Anti-trichomonas screening showed a generally good activity of all compounds (MBC = 0.39-25.0 mug/ml) versus Trichomonas vaginalis, in particular the derivatives 5a,d, 7a, 9 and 11c ranged 0.39-0.78 mug/ml (metronidazole MBC = 12.5 mug/ml). Results of anti-candida assays showed that derivatives 7a, 8a,d and 9 were active against several species of Candida (C. albicans, C. krusei, C. parapsilosis and C. glabrata), having MIC50 between 3.9 and 31.25 mug/ml. The latter compounds were also submitted to anti-mycoplasma assay against Mycoplasma hominis. the results obtained showed that 7a, 8a,d and 9 inhibited the growth of the mycoplasma at the concentration of 0.1 mg/ml. In antibacterial tests only a few compounds showed an MIC50 lower than 62.5 mug/ml against representative strains of Gram-positive and Gram-negative bacteria (Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, Vibrio alginolyticus and Pseudomonas aeruginosa). (C) 2003 Elsevier SAS. All rights reserved.
    DOI:
    10.1016/j.ejmech.2003.11.008
点击查看最新优质反应信息

文献信息

  • Synthesis, anti-mycobacterial, anti-trichomonas and anti-candida in vitro activities of 2-substituted-6,7-difluoro-3-methylquinoxaline 1,4-dioxides
    作者:Antonio Carta、Mario Loriga、Giuseppe Paglietti、Antonella Mattana、Pier Luigi Fiori、Paola Mollicotti、Leonardo Sechi、Stefania Zanetti
    DOI:10.1016/j.ejmech.2003.11.008
    日期:2004.2
    A new series of 23 6,7-difluoro-3-methyl-2-phenylthio/phenylsulfonyl/phenylsulfinyl/benzylamino/phenylamino-quinoxaline 1,4-dioxides variously substituted in the phenyl moiety, was synthesized and submitted to in vitro evaluation for anti-mycobacterial, anti-trichomonas, anti-candida, anti-mycoplasma and antibacterial activities. In anti-mycobacterial assays, several compounds resulted active (MIC90 = 2.0-4.0 mug/ml) against Mycobacterium tuberculosis H37Rv. Anti-trichomonas screening showed a generally good activity of all compounds (MBC = 0.39-25.0 mug/ml) versus Trichomonas vaginalis, in particular the derivatives 5a,d, 7a, 9 and 11c ranged 0.39-0.78 mug/ml (metronidazole MBC = 12.5 mug/ml). Results of anti-candida assays showed that derivatives 7a, 8a,d and 9 were active against several species of Candida (C. albicans, C. krusei, C. parapsilosis and C. glabrata), having MIC50 between 3.9 and 31.25 mug/ml. The latter compounds were also submitted to anti-mycoplasma assay against Mycoplasma hominis. the results obtained showed that 7a, 8a,d and 9 inhibited the growth of the mycoplasma at the concentration of 0.1 mg/ml. In antibacterial tests only a few compounds showed an MIC50 lower than 62.5 mug/ml against representative strains of Gram-positive and Gram-negative bacteria (Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, Vibrio alginolyticus and Pseudomonas aeruginosa). (C) 2003 Elsevier SAS. All rights reserved.
查看更多